Invitrogen™ Human BLC/CXCL13 ELISA Kit

Description

The Human BLC/CSCL13 (Hu BLC) ELISA quantitates Hu BLC in human serum, plasma, or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu BLC. Principle of the method The Human BLC solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.

CXCL13, also known as BCA-1 and Angie, is a small chemokine strongly expressed in the secondary lymphoid organs. It preferentially promotes the migration of B lymphocytes (both B-1 and B-2) to the follicles of the spleen, lymph nodes, and Peyer's patches. It is produced by macrophages, and in mouse the highest constitutive producers include large peritoneal macrophages, Kuppfer cells and lung macrophages (both CD11c+ and CD11c-). The cellular ligand for CXCL13 is CXCR5 also known as BLR-1 (Burkitt’s Lymphoma Receptor 1). CXCR5 is expressed on B cells, Tfh cells and, to a lower degree, some memory T cell populations. CXCL13 plays an important role in the development of chronic lymphocytic leukemia (CCL). CXCL13 is also a plasma biomarker for germinal center activity and generation of broadly neutralizing antibodies against HIV.